Patents Assigned to Factor Bioscience Inc.
  • Patent number: 11904023
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 20, 2024
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11814333
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 14, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Patent number: 11708586
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 25, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11692203
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 4, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11492600
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 8, 2022
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11466293
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 11, 2022
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11339410
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11339409
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11332759
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 17, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11332758
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: May 17, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11242311
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 8, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Patent number: 11241505
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 8, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10982229
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: April 20, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10894092
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 19, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10888627
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 12, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10829738
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 10, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10767195
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 8, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10752918
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 25, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10752576
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: August 25, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Patent number: 10752919
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 25, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde